1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars

As The Firm Prepares For First Generic Rivals For Its Innovative Parkinson’s Drug Rytary

 
• By Urtė Fultinavičiūtė

While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.

A vault full of gold bars
(Shutterstock)

“It is our cup of tea,” is how Amneal’s co-CEO Chirag Patel described the firm’s passion for biosimilars at the recent J.P. Morgan Healthcare Conference.

The firm has previously acknowledged the integration of biosimilars as a key business development priority in 2025. Patel shared...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Business

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By Dave Wallace

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

 
• By Dean Rudge

Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.